title: Intravenous interleukin-1-beta-induced inhibition of gastric emptying: involvement of central corticotrophin-releasing factor and prostaglandin pathways in rats.
abstract: The role of corticotrophin-releasing factor (CRF) and prostaglandin in interleukin-1 beta (IL-1 beta)-induced delayed gastric emptying was investigated. Gastric emptying was monitored 20 min after orogastric delivery of a methylcellulose phenol red solution in fasted rats injected intravenously with IL-1 beta at the ED50 dose (3 ng/rat) 30 min before the non-caloric solution. The IL-1 receptor antagonist (IL-1ra) injected intravenously (3 micrograms/rat) or intracisternally (100 ng/rat) reversed the IL-1 beta-induced 47% inhibition of gastric emptying by 100% and 62%, respectively. The new CRF antagonist [DPhe12, Nle21,38, C alpha MeLeu37]-CRF12-41 (20 micrograms/rat), injected intracisternally, or indomethacin (5 mg/kg i.p.) completely abolished IL-1 beta (3 ng/rat i.v.)-induced gastric stasis. The CRF antagonist injected intravenously (20 micrograms/rat) did not influence the IL-1 beta inhibitory action. None of the pretreatments given alone influenced basal gastric emptying. These data suggest that peripheral IL-1 beta-induced inhibition of gastric emptying is mediated by specific IL-1 receptor interactions and brain CRF pathways requiring the integrity of eicosanoid-cyclooxygenase pathways.
authors.affiliation: Department of Medicine, Gastroenteric Biology Center/UCLA West Los Angeles Medical Center 90073, USA.
authors.forename: G
authors.initials: G
authors.lastname: Sütö
authors.forename: A
authors.initials: A
authors.lastname: Király
authors.forename: V
authors.initials: V
authors.lastname: Plourde
authors.forename: Y
authors.initials: Y
authors.lastname: Taché
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D005746:Gastric Emptying / Q000187:drug effects* / Q000502:physiology*; D007213:Indomethacin / Q000494:pharmacology; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D011453:Prostaglandins / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D012795:Sialoglycoproteins / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011453:Prostaglandins; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D003346:Corticotropin-Releasing Hormone; D007213:Indomethacin